source
- MapLight’s schizophrenia drug misses primary endpoint in Phase 2, shares tumble over 60%MapLight Therapeutics reported results from a mid‑stage Phase 2 trial of its experimental schizophrenia therapy. The study evaluated a once‑daily dosing regimen and failed to meet the predefined p…
- Study shows drug development and reimbursement timelines align across four major marketsResearchers published a cross‑sectional analysis in JAMA Health Forum examining how long it takes for a drug to move from the start of clinical trials to receiving reimbursement approval. The anal…